



MS AF
REPLY UNDER
37 C.F.R. § 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1614

PATENT
1060-0144P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Balázs SÜMEGI Conf.: 8470
Appl. No.: 10/084,095 Group: 1614
Filed: February 28, 2002 Examiner: Spivack, P.
For: PHARMACEUTICAL COMPOSITION HAVING
ENHANCED ANTITUMOR ACTIVITY AND/OR
REDUCED SIDE EFFECTS

REPLY AFTER FINAL UNDER 37 C.F.R. § 1.116

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 25, 2004

Sir:

In response to the Office Action dated January 2, 2004, the due date for Reply having been extended three (3) months to July 2, 2004 by petition herein, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 10 of this paper.


*Please
enter
Amendment.
P. Spivack
8/18/04*

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

IN THE CLAIMS:

Claim 1. (Currently Amended) A pharmaceutical composition having antitumor activity with reduced side effect(s) comprising an effective amount of a known active substance having antitumor effect selected from the group consisting of pyrimidine derivatives or, optionally, a pharmaceutically acceptable acid addition salt thereof, and an effective amount of O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime ~~a hydroxamic acid derivative of the formula I~~



wherein

~~R¹ represents a hydrogen atom or a C₁₋₅ alkyl group,~~

~~R² stands for a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₈ cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or~~